SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
The most important benefit of participating in a clinical trial is that patients get early access to potentially new and successful treatments or screenings before the general public. (Karmanos Cancer ...
Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...
Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare costs. Lifestyle changes and improved diets are critical but often ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results